免疫血浆治疗重症流感的开放标签多中心2期随机研究
该研究为美国29个学术医学中心开展的开放标签、多中心、2期随机试验,评估血凝抑制抗体滴度≥1:80的抗流感血浆治疗重症流感A或B(低氧或呼吸急促)住院儿童和成人(包括孕妇)的安全性和有效性。98例随机分配,确诊流感(PCR)者中血浆+标准治疗组28例(67%)/42例在第28天呼吸状态正常化,标准治疗组24例(53%)/45例,差异未达统计学显著(p=0.069;HR 1.71,95%CI 0.96-3.06)。死亡6例(血浆组1例[2%],标准治疗组5例[10%];HR 0.19,95%CI 0.02-1.65,p=0.093),住院天数和机械通气天数无显著减少,血浆组严重不良事件较少(9例[20%]/46例 vs 20例[38%]/52例,p=0.041)。作者认为血浆治疗对主要终点无显著影响,但似乎安全且耐受良好,3期随机试验正在进行。
要点
- 确诊流感(PCR)患者中,血浆+标准治疗组28例(67%)/42例在第28天呼吸状态正常化,标准治疗组24例(53%)/45例,p=0.069,差异未达统计学显著。
- 血浆+标准治疗组与标准治疗组比较,呼吸状态正常化的HR为1.71(95%CI 0.96-3.06)。
- 死亡6例:血浆+标准治疗组1例(2%),标准治疗组5例(10%),HR 0.19(95%CI 0.02-1.65),p=0.093。
- 血浆+标准治疗组严重不良事件9例(20%)/46例,标准治疗组20例(38%)/52例,p=0.041;最常见为急性呼吸窘迫综合征(1例[2%] vs 2例[4%])和卒中(1例[2%] vs 2例[4%])。
- 住院天数中位数血浆+标准治疗组6天(IQR 4-16)vs 标准治疗组11天(IQR 5-25),p=0.13;机械通气天数中位数0天(IQR 0-6)vs 3天(IQR 0-14),p=0.14,均无显著差异。
适用人群与场景
- 住院儿童和成人(包括孕妇)重症流感A或B,定义为存在低氧或呼吸急促。
- 研究在美国29个学术医学中心进行,实际从29个参与中心中的20个随机分配参与者。
诊断标准与关键阈值
- 重症流感A或B定义:存在低氧或呼吸急促。
- 呼吸状态正常化定义:成人呼吸频率≤20次/分或儿童按年龄界定的20-38次/分阈值,且室内空气氧饱和度≥93%。
- 抗流感血浆血凝抑制抗体滴度≥1:80(针对感染株)。
处置流程与药物剂量
- 血浆+标准治疗组:接受两个单位(或儿科等效剂量)抗流感血浆加标准治疗。
- 标准治疗组:仅接受标准治疗。
- 随访28天。
研究设计与关键结果
- 研究类型:开放标签、多中心、2期随机试验;样本量98例随机分配(113例筛查);人群为住院儿童和成人(包括孕妇)重症流感A或B。
- 干预与对照:抗流感血浆(血凝抑制抗体滴度≥1:80)两个单位(或儿科等效剂量)加标准治疗 vs 单纯标准治疗。
- 主要终点:确诊流感(PCR)患者中,血浆+标准治疗组28例(67%)/42例在第28天呼吸状态正常化,标准治疗组24例(53%)/45例,p=0.069;HR 1.71(95%CI 0.96-3.06)。
- 关键次要终点:死亡6例,血浆+标准治疗组1例(2%),标准治疗组5例(10%),HR 0.19(95%CI 0.02-1.65),p=0.093;住院天数中位数血浆+标准治疗组6天(IQR 4-16)vs 标准治疗组11天(IQR 5-25),p=0.13;机械通气天数中位数血浆+标准治疗组0天(IQR 0-6)vs 标准治疗组3天(IQR 0-14),p=0.14。
- 不良事件:血浆+标准治疗组严重不良事件9例(20%)/46例,标准治疗组20例(38%)/52例,p=0.041;最常见为急性呼吸窘迫综合征(血浆+标准治疗组1例[2%] vs 标准治疗组2例[4%])和卒中(血浆+标准治疗组1例[2%] vs 标准治疗组2例[4%])。
证据类型、等级与局限
- 证据类型:开放标签、多中心、2期随机试验。
- 作者结论:血浆治疗对主要终点无显著影响,但似乎安全且耐受良好;3期随机试验正在进行以进一步评估该干预。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于住院儿童和成人(包括孕妇)重症流感A或B(低氧或呼吸急促),加用抗流感血浆(血凝抑制抗体滴度≥1:80)两个单位(或儿科等效剂量)未显著改善第28天呼吸状态正常化,但似乎安全且耐受良好;作者认为3期随机试验正在进行以进一步评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Influenza causes substantial morbidity and mortality despite available treatments. Anecdotal reports suggest that plasma with high antibody titres to influenza might be of benefit in the treatment of severe influenza.
METHODS: In this randomised, open-label, multicentre, phase 2 trial, 29 academic medical centres in the USA assessed the safety and efficacy of anti-influenza plasma with haemagglutination inhibition antibody titres of 1:80 or more to the infecting strain. Hospitalised children and adults (including pregnant women) with severe influenza A or B (defined as the presence of hypoxia or tachypnoea) were randomly assigned to receive either two units (or paediatric equivalent) of anti-influenza plasma plus standard care, versus standard care alone, and were followed up for 28 days. The primary endpoint was time to normalisation of patients' respiratory status (respiratory rate of ≤20 breaths per min for adults or age-defined thresholds of 20-38 breaths per min for children) and a room air oxygen saturation of 93% or more. This study is registered with ClinicalTrials.gov, number NCT01052480.
FINDINGS: Between Jan 13, 2011, and March 2, 2015, 113 participants were screened for eligibility and 98 were randomly assigned from 20 out of 29 participating sites. Of the participants with confirmed influenza (by PCR), 28 (67%) of 42 in the plasma plus standard care group normalised their respiratory status by day 28 compared with 24 (53%) of 45 participants on standard care alone (p=0·069). The hazard ratio (HR) comparing plasma plus standard care with standard care alone was 1·71 (95% CI 0·96-3·06). Six participants died, one (2%) from the plasma plus standard care group and five (10%) from the standard care group (HR 0·19 [95% CI 0·02-1·65], p=0·093). Participants in the plasma plus standard care group had non-significant reductions in days in hospital (median 6 days [IQR 4-16] vs 11 days [5-25], p=0·13) and days on mechanical ventilation (median 0 days [IQR 0-6] vs 3 days [0-14], p=0·14). Fewer plasma plus standard care participants had serious adverse events compared with standard care alone recipients (nine [20%] of 46 vs 20 [38%] of 52, p=0·041), the most frequent of which were acute respiratory distress syndrome (one [2%] vs two [4%] patients) and stroke (one [2%] vs two [4%] patients).
INTERPRETATION: Although there was no significant effect of plasma treatment on the primary endpoint, the treatment seemed safe and well tolerated. A phase 3 randomised trial is now underway to further assess this intervention.
FUNDING: National Institute of Allergy and Infectious Diseases, US National Institutes of Health.
参考来源
- Beigel JH, Tebas P, Elie-Turenne MC, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017. PMID: 28522352. doi:10.1016/S2213-2600(17)30174-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。